
Rare find: Remains of large, shortfin mako shark found in eastern Nova Scotia
The Halifax-based Marine Animal Response Society says the remains of a large, shortfin mako shark — considered the fastest shark in the ocean — were found Saturday along the shoreline near Port Dufferin, N.S., about 140 kilometres east of Halifax.
Executive Director Tonya Wimmer said Monday it remains unclear how the adult, 3.6-metre female died.
ARTICLE CONTINUES BELOW
'It wasn't in the greatest shape,' Wimmer said in an interview, adding that the animal was too decomposed to allow for a necropsy. 'She likely would have been there for a few days .... And there wasn't anything on the animal externally to give us any clues as to why it would be in this location.'
It is unusual to find this type of shark near shore.
'They're usually offshore in warmer waters in the Gulf Stream, on the banks,' Wimmer said. 'It is a very rare thing for them to be this close to shore. But it has happened over the years.'
According to the federal fisheries department, shortfin makos can grow to 3.9 meters in length, and they can swim at speeds reaching 68 kilometres per hour.
'It's an absolutely amazing animal,' Wimmer said. 'These are the fastest sharks that exist. They are phenomenal ... And they have these aerial displays at times when they'll jump out of the water.'
Makos have been known to jump as high as six metres above the water.
As well, they frequent Browns Bank on the continental shelf off southwestern Nova Scotia, as well as the Gulf of St. Lawrence. They swim as far south as Argentina.
And they have a particularly intimidating look.
'The teeth are slender and slightly curved ... and are visible even when the mouth is closed, giving it a fearsome appearance,' the fisheries department says on its website. As for their colouring, the department says they have white undersides and 'metallic indigo blue' topsides.
ARTICLE CONTINUES BELOW
ARTICLE CONTINUES BELOW
They mainly eat squid, mackerel, tuna, bonitos and swordfish. But other sharks and porpoises are sometimes on the menu.
'It is rarely encountered by swimmers or divers due to its oceanic nature and should be treated with respect and caution,' the department says. 'The mako has been known to attack boats on occasion but most of these attacks are usually linked to being hooked by game fishers and are considered abnormal behaviour.'
Little else is known about this elusive species, which was designated as endangered in 2019 by the independent Committee on the Status of Endangered Wildlife in Canada. The mako population is primarily threatened by longline fisheries that are trying to catch other fish.
In recent years, there has been an increase in shark sightings along Canada's East Coast, with reports of great white sharks getting most of the attention. Last July, the Ocean Tracking Network at Dalhousie University in Halifax confirmed it was working on a plan to to post warning signs for beachgoers for the first time.
Experts say conservation measures had helped the great white shark population recover from a drastic decline in the 1970s and 1980s. As well, they said climate change had led to warmer ocean temperatures, making it easier for many ocean species to spread northward.
But Wimmer said it's too early to tell what is happening with the makos.
'Climate change is affecting a lot of the marine animals in our ocean. We've seen it with whales, we've seen it with other species .... (But) we don't have a lot of information on makos. It is something still to be determined.'
ARTICLE CONTINUES BELOW
ARTICLE CONTINUES BELOW
In 2002, several makos were caught during a shark fishing derby 16 kilometres from Halifax harbour. Two years later, a massive 1,085-pound mako was landed in Yarmouth, N.S., where it was hauled away with a forklift, its gaping jaws showing rows of hooked teeth.
Still, makos are seldom found in waters colder than 16 C, experts say.
This report by The Canadian Press was first published June 16, 2025.
— By Michael MacDonald in Halifax
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
5 days ago
- Cision Canada
Imfinzi approved in Canada as first and only perioperative immunotherapy for muscle invasive bladder cancer Français
MISSISSAUGA, ON, Aug. 6, 2025 /CNW/ - Health Canada has granted a Notice of Compliance (NOC) for Imfinzi ® (durvalumab) for the treatment of patients with resectable muscle invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by adjuvant Imfinzi monotherapy treatment after radical cystectomy. The approval is based on results from the NIAGARA Phase III trial, which were published in The New England Journal of Medicine. 1, 2 In a planned interim analysis, the Imfinzi-based perioperative regimen demonstrated a statistically significant and clinically meaningful 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus neoadjuvant chemotherapy with radical cystectomy alone (based on event-free survival [EFS] hazard ratio [HR] of 0.68; 95% confidence interval [CI] 0.56-0.82; p<0.0001). Estimated median EFS was not yet reached for the Imfinzi plus gemcitabine and cisplatin arm versus 46.1 months for the comparator arm. An estimated 67.8% of patients treated with the regimen were event free at two years compared to 59.8% in the comparator arm. 2 Results from the key secondary endpoint of overall survival (OS) showed that the Imfinzi-based perioperative regimen reduced the risk of death by 25% versus the comparator arm (based on OS HR of 0.75; 95% CI 0.59-0.93; p=0.011). Median survival was not yet reached for either arm. An estimated 82.2% of patients treated with the regimen were alive at two years compared to 75.2% in the comparator arm. 2 Imfinzi was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings. The most common adverse events (any Grade, occurring in ≥10% of patients) for the Imfinzi plus chemotherapy arm were nausea (53.6%), fatigue (51.5%), neutropenia (40.4%), anemia (38.7%), constipation (38.7%), decreased appetite (26.6%), rash (20.9%), pyrexia (20.8%), diarrhea (20.6%), abdominal pain (20.2%), vomiting (19.2%), blood creatine increased (18.5%), thrombocytopenia (17.2%), pruritus (15.1%), hypothyroidism (12.6%), neuropathy peripheral (12.5%), leukopenia (10.9%), and aspartate aminotransferase increased (10.4%). 1 "Health Canada's approval of this durvalumab-based perioperative regimen represents a major advance for Canadians with muscle invasive bladder cancer, where nearly half will relapse despite curative treatment," says Dr. Srikala Sridhar, Professor of Medicine at the University of Toronto, Genitourinary Medical Oncologist at the Princess Margaret Cancer Centre and NIAGARA trial investigator. "Findings from the NIAGARA trial showed that this new regimen reduces risk of recurrence and significantly improves survival – which may offer new hope and potential to transform care in this setting." "The high rate of recurrence associated with muscle invasive bladder cancer is an ongoing challenge and source of concern for physicians and patients," says Dr. Normand Blais, Medical Oncologist at the Centre hospitalier de l'Université de Montréal. "The Health Canada approval based on results from the NIAGARA trial may now offer us the opportunity to increase the chance of better patient outcomes and long-term survival by the use of immunotherapy in this setting, which is very good news for patients and their families." Bladder cancer is the 5th most common cancer in Canada, with more than 13,000 patients diagnosed each year. 3 The most common type of bladder cancer is urothelial carcinoma, which begins in the urothelial cells of the urinary tract. Bladder cancer is considered muscle invasive when there is evidence of the tumour invading the muscle wall of the bladder but no distant metastases. 4 In MIBC, approximately 50% of patients who undergo bladder removal surgery experience disease recurrence. 5 Treatment options that prevent disease recurrence after surgery are critically needed in this curative-intent setting. "This decision by Health Canada represents an important step forward for all Canadians affected by muscle invasive bladder cancer," says Michelle Colero, Executive Director, Bladder Cancer Canada. "For many patients and families, the fear of recurrence after surgery has been overwhelming. This new treatment option may offer renewed hope for longer, healthier lives." About NIAGARA 2 NIAGARA is a randomized, open-label, multi-centre, global Phase III trial evaluating perioperative Imfinzi as treatment for patients with MIBC before and after radical cystectomy. In the trial, 1,063 patients were randomized to receive four cycles of Imfinzi plus neoadjuvant chemotherapy prior to cystectomy followed by eight cycles of Imfinzi monotherapy, or neoadjuvant chemotherapy alone prior to cystectomy with no further treatment after surgery. NIAGARA is the largest global Phase III trial in this setting to date. The trial is being conducted at 192 centres in 22 countries across North America (including Canada), South America, Europe, Australia and Asia. Its dual primary endpoints are EFS and pathologic complete response at the time of cystectomy. Key secondary endpoints are OS and safety. About Imfinzi Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical business whose innovative medicines are used by millions of patients worldwide. The company's core areas of scientific focus are Oncology; Cardiovascular, Renal and Metabolic (CVRM); Rare Disease; Respiratory & Immunology; and Vaccine & Immune Therapies. In Canada, the company employs more than 2,400 people and recently announced a major expansion of its research footprint in Mississauga – including the expansion of its AstraZeneca R&D Hub and the creation of a new Alexion Development Hub for Rare Diseases. AstraZeneca was recently recognized as one of Canada's Top 100 Employers, one of Canada's Most Admired Corporate Cultures, and a Greater Toronto Top Employer. AstraZeneca is committed to contributing to a more sustainable future for people, society and planet taking important steps to help tackle some of the most pressing sustainability challenges globally – from climate and biodiversity loss, to health equity and health system resilience. AstraZeneca was one of the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative (SBTi) Corporate Net-Zero Standard. For more information, please visit the company's website at Imfinzi ® and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc. SOURCE AstraZeneca Canada Inc.


Toronto Star
6 days ago
- Toronto Star
Yatiri Bio Acquires NGeneBioAI to Expand AI-Powered Proteomics Platform and Advance Precision Biomarker Discovery
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Yatiri Bio, Inc., a leader in proteomics-driven precision medicine, today announced the successful acquisition of NGeneBioAI, Inc., a San Diego-based company specializing in plasma proteomics and AI-powered diagnostics. The acquisition strengthens Yatiri Bio's position at the forefront of biomarker discovery and translational drug development. The transaction includes the transfer of all NGeneBioAI assets, proprietary technologies, commercial agreements, and intellectual property in accordance with applicable agreements. As part of the deal, Yatiri Bio issued common stock to NGeneBio, the parent company of NGeneBioAI.


CBC
7 days ago
- CBC
Close encounter with a great white shark near Halifax
Geraldine Fernandez and Neil Hammerschlag tell The National about the moment a male great white shark made a surprise appearance during a research expedition off the coast of Halifax.